Cellmid reveals MK preclinical trial results
The study results suggested that MK has showed 27% reduction in the area of heart muscle damage as compared to untreated animals undergoing the same procedure. Dose-ranging studies
miRecule has signed a research collaboration with EM subsidiary Rio Biofarma Brasil (RBBL) to co-develop peptide-mediated delivery technologies aimed at improving targeted ribonucleic acid (RNA) therapeutics delivery to tissues beyond the liver and muscles in a range of disease areas.